Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.34 |
| ▸ | PPARG | P37231 | 7/20 | 0.34 |
| ▸ | PPARD | Q03181 | 7/20 | 0.34 |
| ▸ | PPARA | Q07869 | 7/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.34 |
| ▸ | TSHR | P16473 | 4/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.34 |
| ▸ | TLR2 | O60603 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | FABP4 | P15090 | 2/20 | 0.34 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.34 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8673179 | 0.94 | AKR1B1 (0.43) | CES1CES2ALDH1A1AKR1B1GPR84 | |
| SCHEMBL8673175 | 0.94 | AKR1B1 (0.43) | CES1CES2ALDH1A1AKR1B1GPR84 | |
| SCHEMBL540776 | 0.93 | GPR84 (0.45) | CES1CES2ALDH1A1AKR1B1GPR84 | |
| SCHEMBL7546476 | 0.92 | CES1 (0.41) | CES1CES2ALDH1A1AKR1B1TP53 | |
| SCHEMBL7542632 | 0.89 | AKR1B1 (0.45) | CES1CES2ALDH1A1AKR1B1GPR84 | |
| SCHEMBL7552128 | 0.89 | CES1 (0.39) | CES1CES2ALDH1A1AKR1B1TP53 | |
| SCHEMBL3923583 | 0.88 | FFAR3 (0.37) | CES1CES2ALDH1A1TSHR | |
| SCHEMBL19357539 | 0.88 | FFAR3 (0.37) | CES1CES2ALDH1A1TSHR | |
| SCHEMBL7542466 | 0.87 | KMT2A (0.47) | CES1CES2ALDH1A1AKR1B1GPR84 | |
| SCHEMBL7548078 | 0.87 | KMT2A (0.47) | CES1CES2ALDH1A1AKR1B1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107343965-B | Bone adhesive and preparation method thereof | 中国科学院化学研究所 | 2020-04-24 | — | — | CN | claimed |
| WO-2017046037-A1 | NANOPARTICLES LOADED WITH ACTIVE INGREDIENTS, THEIR PROCESS OF PREPARATION AND THEIR USES | ONXEO (FR) | 2017-03-23 | — | — | WO | claimed |
| US-20170071866-A1 | NANOPARTICLES LOADED WITH ACTIVE INGREDIENTS, THEIR PROCESS OF PREPARATION, AND THEIR USES | ONXEO S.A. (FR) | 2017-03-16 | — | — | US | claimed |
| US-20020065314-A1 | COMPOSITIONS AND METHOD FOR STIMULATING HAIR GROWTH | S.N. BIOTECH, INC. | 2002-05-30 | — | — | US | claimed |
| US-12433846-B2 | Drug delivery system for treatment of cancer | SINTEF TTO AS (NO) | 2025-10-07 | — | — | US | disclosed |
| US-11957793-B2 | Nanoparticles | SINTEF TTO AS (NO) | 2024-04-16 | — | — | US | disclosed |
| US-11806330-B2 | PACA and cabazitaxel for anti-cancer treatment | SINTEF TTO AS (NO) | 2023-11-07 | — | — | US | disclosed |
| US-20220257525-A1 | DRUG DELIVERY SYSTEM FOR TREATMENT OF CANCER | SINTEF TTO AS (NO) | 2022-08-18 | — | — | US | disclosed |
| EP-3840736-B1 | NANOPARTICLES | SINTEF TTO AS (NO) | 2022-06-15 | — | — | EP | disclosed |
| EP-3946253-A1 | POLY (ALKYL CYANOACRYLATE) NANOPARTICLES FOR USE IN TREATMENT OF CANCER | Sintef TTO AS (NO) | 2022-02-09 | — | — | EP | disclosed |
| US-20210236435-A1 | Nanoparticles | SINTEF TTO AS (NO) | 2021-08-05 | — | — | US | disclosed |
| EP-3840736-A1 | NANOPARTICLES | Sintef TTO AS (NO) | 2021-06-30 | — | — | EP | disclosed |
| CN-107343965-B | Bone adhesive and preparation method thereof | 中国科学院化学研究所 | 2020-04-24 | — | — | CN | disclosed |
| US-20200061019-A1 | DRUG DELIVERY SYSTEM FOR TREATMENT OF CANCER | SINTEF TTO AS (NO) | 2020-02-27 | — | — | US | disclosed |
| WO-2020039081-A1 | NANOPARTICLES | SINTEF TTO AS (NO) | 2020-02-27 | — | — | WO | disclosed |
| US-20190298682-A1 | PACA AND CABAZITAXEL FOR ANTI-CANCER TREATMENT | OSLO UNIVERSITETSSYKEHUS HF (NO) | 2019-10-03 | — | — | US | disclosed |
| WO-2017046037-A1 | NANOPARTICLES LOADED WITH ACTIVE INGREDIENTS, THEIR PROCESS OF PREPARATION AND THEIR USES | ONXEO (FR) | 2017-03-23 | — | — | WO | disclosed |
| US-20170071866-A1 | NANOPARTICLES LOADED WITH ACTIVE INGREDIENTS, THEIR PROCESS OF PREPARATION, AND THEIR USES | ONXEO S.A. (FR) | 2017-03-16 | — | — | US | disclosed |
| US-20020065314-A1 | COMPOSITIONS AND METHOD FOR STIMULATING HAIR GROWTH | S.N. BIOTECH, INC. | 2002-05-30 | — | — | US | disclosed |
| US-5767152-A | USING A CYANOCARBOXYLIC ACID | S.N. BIOTECH, INC. | 1998-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170071866-A1 | NANOPARTICLES LOADED WITH ACTIVE INGREDIENTS, THEIR PROCESS OF PREPARATION, AND THEIR USES | MPO, EXOSC9, CD63 | CES1 2164/4885CES2 1697/4885ALDH1A1 1742/4885 |
| US-20210236435-A1 | Nanoparticles | CBR3, CBR1, AKR1C3 | CES1 413/4885CES2 270/4885ALDH1A1 26/4885 |
| US-11957793-B2 | Nanoparticles | CBR3, CBR1, AKR1C3 | CES1 419/4885CES2 433/4885ALDH1A1 24/4885 |
| US-20020065314-A1 | COMPOSITIONS AND METHOD FOR STIMULATING HAIR GROWTH | AREG, NGF, HDGF | CES1 4040/4885CES2 3225/4885ALDH1A1 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.